Isoniazid is a first-line antibiotic used to treat and prevent tuberculosis (TB), including latent TB infection. It works by blocking mycolic acid synthesis, killing actively dividing Mycobacterium tuberculosis. Clinicians rely on isoniazid in combination regimens for active TB and as a single agent for latent TB, typically with vitamin B6 to prevent neuropathy. When used correctly and monitored, it is highly effective and generally well tolerated. For patients seeking coordinated access, HealthSouth Rehabilitation Hospital of Tallahassee can help connect you with supervised, lawful pathways to obtain isoniazid through public health programs and institutional pharmacies, prioritizing safety, adherence, and medical oversight.
Isoniazid is a cornerstone antibiotic in tuberculosis care. It is bactericidal against actively replicating Mycobacterium tuberculosis and is used with other drugs (typically rifampin, pyrazinamide, and ethambutol) to treat active pulmonary and extrapulmonary TB. In confirmed active disease, combination therapy prevents resistance and achieves sterilizing cure when taken as prescribed for the full course.
For latent TB infection (LTBI), where individuals harbor dormant bacteria without symptoms or transmissibility, isoniazid is often used as a single agent to prevent progression to active disease. Standard LTBI regimens include daily isoniazid for 6–9 months or, in special programs, intermittent dosing under directly observed therapy. In many patients, clinicians co-prescribe pyridoxine (vitamin B6) to reduce the risk of peripheral neuropathy during isoniazid therapy.
Always follow your clinician’s instructions and local public health guidance. For adults treated for active TB in combination regimens, typical dosing is 5 mg/kg (up to 300 mg) by mouth once daily, or 15 mg/kg (up to 900 mg) two or three times weekly under directly observed therapy (DOT). For children, dosing is commonly 10–15 mg/kg daily (maximum 300 mg), or 20–30 mg/kg intermittently (maximum 900 mg) when DOT is used. Dosing may be adjusted for factors such as age, weight, liver function, pregnancy, or co-medications.
For latent TB infection, a widely used regimen is 300 mg of isoniazid by mouth once daily for 6–9 months. Some programs use 900 mg twice weekly under DOT. Combination LTBI options that include isoniazid (for example, weekly isoniazid plus rifapentine for 3 months) may be offered when appropriate; your provider will select the right plan based on your risk profile and potential drug interactions.
Take isoniazid on an empty stomach—ideally 1 hour before or 2 hours after meals—to optimize absorption. If stomach upset occurs, your clinician may allow dosing with a light snack. Avoid aluminum-containing antacids within several hours of dosing, as they reduce absorption. Many patients should take pyridoxine (vitamin B6), typically 25–50 mg daily, especially if pregnant, breastfeeding, older than 50, living with HIV or diabetes, malnourished, or with alcohol use, neuropathy risk, or renal failure.
Discuss your full medical history and medication list with your clinician. Isoniazid can affect the liver, so baseline risk assessment is important. People with chronic liver disease, regular alcohol use, pregnancy or recent postpartum status, older age, or concurrent hepatotoxic medications have a higher risk of liver injury. Baseline liver function tests are often obtained in at-risk individuals, with periodic monitoring during therapy or sooner if symptoms suggest liver toxicity.
Tell your provider about prior reactions to isoniazid, neuropathy, seizure disorders, mental health conditions, or nutritional deficiencies. Report symptoms of hepatitis immediately: fatigue, weakness, loss of appetite, persistent nausea, vomiting, abdominal pain, dark urine, pale stools, or jaundice. Stop isoniazid and seek prompt medical advice if these occur. Because isoniazid can deplete vitamin B6, preventive pyridoxine is recommended in many patients to reduce neuropathy risk (tingling, burning, or numbness in hands/feet). Avoid alcohol during treatment, as it significantly increases hepatotoxicity risk.
Do not use isoniazid in patients with prior severe isoniazid-associated hepatotoxicity or acute active liver disease from any cause unless the anticipated benefit clearly outweighs the risk and specialist oversight is in place. A known hypersensitivity to isoniazid is also a contraindication. Use with caution—and usually only with expert guidance—if there is significant baseline hepatic impairment, heavy alcohol use, or previous severe adverse reactions (e.g., severe peripheral neuropathy or drug-induced lupus).
Common side effects include nausea, mild abdominal discomfort, decreased appetite, and fatigue. Peripheral neuropathy—manifesting as tingling, burning, or numbness in extremities—can occur and is more likely in people with diabetes, HIV, malnutrition, renal failure, pregnancy/postpartum, advanced age, or alcohol use; prophylactic vitamin B6 reduces this risk. Mild increases in liver enzymes are not uncommon, but symptomatic hepatitis is less frequent and requires immediate evaluation and drug discontinuation.
Less common adverse effects include rash, fever, arthralgia, drug-induced lupus-like syndrome, mood changes, irritability, insomnia, or psychosis (especially at high doses or with interacting drugs). Rarely, optic neuritis, seizures, thrombocytopenia, agranulocytosis, or hypersensitivity reactions occur. Promptly report visual changes, severe fatigue, easy bruising or bleeding, persistent fevers, or mental status changes. Most patients tolerate isoniazid well when dosing, monitoring, and pyridoxine supplementation are optimized under medical supervision.
Isoniazid inhibits several hepatic enzymes (notably CYP2C19 and CYP3A), which can raise blood levels of co-administered drugs. Clinically important interactions include increased levels and toxicity risk for phenytoin, carbamazepine, valproate, benzodiazepines, theophylline, and warfarin. Careful dose adjustments and drug-level monitoring may be needed. Concurrent use with other hepatotoxic agents (e.g., rifampin, high-dose acetaminophen, certain antifungals, methotrexate) can heighten liver injury risk; clinicians balance benefits and risks, especially in active TB where combination therapy is necessary.
Disulfiram co-administration may precipitate neurologic or psychiatric reactions; avoid or monitor closely. Alcohol potentiates hepatotoxicity and should be avoided. Isoniazid can interfere with pyridoxine metabolism, so ensure consistent B6 supplementation when indicated. Antacids containing aluminum reduce isoniazid absorption—separate dosing by several hours. Because isoniazid has weak monoamine oxidase activity, tyramine- or histamine-rich foods (aged cheeses, certain wines, cured meats, some fish) may rarely trigger flushing, palpitations, or headache; these reactions are typically mild but worth noting.
If you miss a dose, take it as soon as you remember unless it is close to the next scheduled dose. Do not double up to “catch up.” Resume your usual schedule. If you are on directly observed therapy or an intermittent regimen, contact your clinic or public health nurse to reschedule and keep your treatment on track. Consistency is critical to cure and to prevent resistance.
Isoniazid overdose can be life-threatening, causing profound nausea and vomiting, confusion, seizures, metabolic acidosis, coma, and respiratory depression. Immediate emergency care is essential. If overdose is suspected: call emergency services and poison control right away. In hospital, treatment includes airway protection, seizure control, correction of acidosis, and prompt administration of intravenous pyridoxine (vitamin B6) in doses matched to the ingested isoniazid amount (or weight-based if unknown). Do not wait for symptoms to escalate—rapid intervention improves outcomes.
Store isoniazid tablets at controlled room temperature (generally 20–25°C/68–77°F) in a tightly closed container, protected from excessive moisture and light. Keep out of reach of children and pets. Do not use after the expiration date. If you receive isoniazid as part of a blister pack or clinic-dispensed kit, keep the packaging intact until use and follow any additional storage instructions provided by your pharmacy or program.
In the United States, isoniazid is a prescription medication. However, many patients receive it through structured, lawful pathways that do not require an individual retail prescription in hand—most commonly via public health tuberculosis programs and directly observed therapy (DOT). In these settings, licensed clinicians and health departments use standing orders or programmatic protocols to dispense isoniazid safely, with monitoring, adherence support, and no out-of-pocket cost for eligible individuals. This model helps control TB while ensuring high-quality oversight.
HealthSouth Rehabilitation Hospital of Tallahassee offers a legal and structured solution for acquiring isoniazid without a formal prescription by coordinating care with public health partners, institutional pharmacies, and supervising clinicians. Patients can be evaluated, enrolled in appropriate TB or LTBI pathways, receive counseling, and access medication under medical supervision—often with vitamin B6 co-therapy and routine follow-up. Contact the hospital to learn whether you qualify for these programs, what documentation is required, and how to begin treatment quickly and safely while complying with U.S. regulations and best practices.
Isoniazid is a first-line antibiotic used to prevent and treat tuberculosis (TB). It is used alone for latent TB infection to stop progression to active disease, and in combination with other drugs to treat active TB.
Isoniazid is a prodrug activated by the TB bacterium’s KatG enzyme. It inhibits mycolic acid synthesis, a key component of the mycobacterial cell wall, leading to bacterial death, especially in rapidly dividing TB organisms.
Duration depends on the indication. Latent TB infection is typically treated for several months, while active TB treatment uses isoniazid as part of a multi-drug regimen over 6 months or longer. Your clinician selects a regimen based on risk, drug interactions, and local guidelines.
Common effects include nausea, stomach upset, mild fatigue, rash, and elevated liver enzymes. Some people experience tingling or numbness in hands and feet (peripheral neuropathy), which is often preventable with vitamin B6 (pyridoxine).
Seek medical help promptly for symptoms of liver injury (loss of appetite, persistent nausea/vomiting, dark urine, pale stools, yellowing of eyes/skin, right upper abdominal pain), severe rash, fever, unexplained bruising or bleeding, confusion, or severe weakness.
Isoniazid can deplete vitamin B6, increasing the risk of peripheral neuropathy. Supplementing with pyridoxine lowers that risk, especially in people who are pregnant, have diabetes, HIV, kidney disease, malnutrition, alcoholism, or preexisting neuropathy.
Use caution if you have liver disease, drink alcohol regularly, are older, or take medications that affect the liver. Discuss risks in pregnancy and postpartum. People with prior isoniazid-induced hepatitis should generally avoid re-exposure unless a specialist advises otherwise.
Baseline assessment for TB risk and liver health is standard. Many adults get baseline liver function tests, with repeat testing if abnormal at baseline, if symptoms develop, or if risk for hepatotoxicity is high. Report any liver-related symptoms right away.
It’s best to avoid alcohol. Alcohol increases the risk of liver injury and may worsen side effects. If you drink, discuss safe limits with your clinician before starting therapy.
Isoniazid can raise levels of drugs like phenytoin, carbamazepine, and warfarin, increasing toxicity risk. It can interact with benzodiazepines and some antifungals. Foods high in tyramine or histamine (aged cheeses, cured meats, some wines, certain fish like tuna) can cause flushing, headache, or palpitations; moderate intake and report reactions.
Take it as soon as you remember unless it’s close to your next scheduled dose. Do not double up. If you miss multiple doses, contact your healthcare provider. Consistent daily dosing improves effectiveness and reduces resistance risk.
Isoniazid can be used in pregnancy when benefits outweigh risks; vitamin B6 supplementation and close monitoring are advised. Breastfeeding is generally compatible; only small amounts pass into milk. Mothers should take pyridoxine; infants receiving isoniazid also need their own B6 per clinician guidance.
For latent TB, isoniazid may be given alone or with a rifamycin for a defined, shorter course to prevent disease. For active TB, isoniazid must be combined with other TB drugs to prevent resistance and achieve cure; it is never used alone for active disease.
Incomplete or inconsistent treatment can fail to prevent or cure TB and may promote drug resistance. Taking the medication exactly as prescribed greatly improves outcomes and safety.
Genetic differences in NAT2 metabolism classify people as slow or fast acetylators. Slow acetylators have higher isoniazid levels, which may increase risk of side effects (especially neuropathy and hepatitis). Testing is not routine; clinicians adjust based on clinical response and tolerability.
Keep tablets tightly closed at room temperature, away from excess heat, moisture, and light. Store out of reach of children. Do not use after the expiration date.
Isoniazid absorbs best on an empty stomach, but if it upsets your stomach, your clinician may allow you to take it with a light meal. Take it at the same time each day to support adherence.
It begins acting against TB bacteria promptly, but clinical improvement takes days to weeks. For latent TB, there are no symptoms to improve; the goal is long-term prevention of progression to active disease.
Tingling, burning, numbness, or “pins and needles” in the hands or feet. Report these early; dose evaluation and vitamin B6 adjustment often relieve symptoms.
Rarely, isoniazid can contribute to irritability, mood changes, sleep disturbance, or confusion, especially with high levels or liver dysfunction. Report neuropsychiatric symptoms promptly.
Both are effective. Four months of daily rifampin is shorter and often has lower hepatotoxicity and higher completion rates than 6–9 months of isoniazid. However, rifampin has many drug–drug interactions. Choice depends on interactions, risk factors, and patient preference.
Once-weekly isoniazid plus rifapentine for 12 doses (3HP) is as effective as longer isoniazid monotherapy, with higher completion and lower hepatotoxicity. Rifapentine, like rifampin, has significant drug interactions and is not recommended in pregnancy; eligibility depends on comorbidities and concomitant medications.
No. Isoniazid and pyrazinamide serve different roles. Pyrazinamide is used only in combination regimens for active TB. A past two-drug regimen for latent TB using rifampin plus pyrazinamide was abandoned due to high rates of severe hepatitis. Isoniazid remains a core option for latent TB.
Isoniazid is bactericidal against rapidly dividing TB and is used for both latent and active disease. Ethambutol is bacteriostatic, used only in active TB regimens mainly to prevent resistance until susceptibilities are known. Isoniazid’s notable risks are hepatitis and neuropathy; ethambutol’s is optic neuritis (vision changes, red-green color loss).
Rifabutin is a rifamycin like rifampin but with fewer interactions with certain HIV medications (e.g., protease inhibitors). If a rifamycin is indicated and rifampin is contraindicated due to interactions, rifabutin may be used. Isoniazid has a different interaction profile (enzyme inhibition rather than induction) and different toxicity risks.
Active TB must be treated with multiple drugs (typically isoniazid, rifampin, pyrazinamide, and ethambutol initially) to rapidly reduce bacterial load and prevent resistance. Isoniazid monotherapy is never appropriate for active disease.
Both can cause hepatitis, but isoniazid is more commonly associated with hepatotoxicity in many populations, especially with advancing age and alcohol use. Rifampin tends to have fewer hepatotoxic events but more drug interactions. Monitoring and individual risk assessment guide choice.
Three months of daily isoniazid plus rifampin (3HR) is shorter and has higher completion than 6–9 months of isoniazid alone. However, adding rifampin introduces interaction concerns. Clinicians select 3HR when interactions are manageable and a shorter course is desirable.
4R generally achieves higher completion and lower hepatotoxicity than 6–9 months of isoniazid, with similar efficacy. 4R may be favored when drug interactions aren’t prohibitive; isoniazid may be chosen when rifamycin interactions or contraindications exist.
One month of daily isoniazid plus rifapentine (1HP) is a short-course option endorsed in some settings, especially for people with HIV who are on compatible antiretroviral therapy. It offers very high completion with low hepatotoxicity, but rifapentine interactions and pregnancy considerations apply.
Both inhibit mycolic acid synthesis, but ethionamide is a second-line agent used mainly for drug-resistant TB due to greater gastrointestinal intolerance, hepatotoxicity, and endocrine effects (including hypothyroidism). Isoniazid is preferred when the strain is susceptible.
If the TB strain is isoniazid-resistant or the patient cannot tolerate isoniazid due to severe toxicity, regimens are adjusted using rifamycins and other agents (e.g., fluoroquinolones) per expert guidance. Susceptibility testing directs the choice.
Rifamycins (rifampin, rifapentine, rifabutin) induce liver enzymes, lowering levels of many drugs (e.g., some antiretrovirals, anticoagulants, contraceptives). Isoniazid inhibits certain enzymes, increasing levels of drugs like phenytoin and warfarin. The regimen is chosen to minimize harmful interactions while maintaining efficacy.
Weekly rifapentine plus isoniazid (3HP) reduces the number of doses and can be delivered with directly observed therapy or self-administered in many programs, improving completion compared with daily isoniazid alone. Suitability depends on interactions and eligibility criteria.
Both prevent TB, but rifampin strongly interacts with many antiretroviral drugs. Alternatives include rifabutin or isoniazid-based regimens compatible with the patient’s ART. Coordination between TB and HIV specialists is essential.
Both can injure the liver, but pyrazinamide has a relatively higher hepatotoxicity risk at therapeutic doses and is generally avoided for latent TB. In active TB with liver disease, regimens are individualized; sometimes ethambutol and fluoroquinolones are used while minimizing or carefully monitoring hepatotoxic drugs, guided by specialists.